City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today ...

RNA interference (RNAi) technology has emerged as one of the most promising innovations in molecular biology and biotechnology, with high potential in therapeutic, agricultural, and research ...

RNA interference (RNAi) is an ancient genetic regulatory mechanism that modern-day scientists are trying to harness. Since its discovery more than 10 years ago, RNAi R&D has run the gamut from ...

What is Short Hairpin RNA? RNA serves a wide variety of roles within a cell, carrying out catalytic, regulatory, structural and genetic transferal functions. A type of artificial RNA, called short ...

The Food and Drug Administration on Friday granted the first U.S. approval of a drug that works by 'silencing' genes to halt disease, completing a 16-year research journey for Alnylam Pharmaceuticals, ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Alnylam and Collaborators Publish New Pre-clinical Results on Ex Vivo Applications of RNAi to Enhance Dendritic Cell Vaccines for Cancer – RNAi Silencing of PD-1 Ligands Significantly Boosts Dendritic ...

The first sprayable insecticide made of RNA can target and kill ravenous Colorado potato beetles while sparing most ...

RNA interference (RNAi) is a key biological process that leads to the silencing of gene expression. RNAi can be initiated by a cell in response to pathogenic nucleic acids to bring about a targeted ...

- Company Expects to Initiate a Phase 1 Study in Early-Onset Alzheimer’s Disease in Early 2022, with Initial Human Data at or Around Year-End 2022 - - ALN-APP Marks the Industry’s First-Ever RNAi ...

Responsible for global chickpea losses of around USD 330 million annually, the pest not only threatens chickpeas but also infests cotton, pigeonpea, maize, tomato, and other crops ...